Affamed Technologies Completes First-in-China Implantation in Pivotal Clinical Trial of MINI WELL® Extended Depth-of-Focus Intraocular Lens

ShanghaiMarch 3, 2023PR Newswire -- AffaMed Technologies, a joint venture established in China by Affamed Technologies and SIFI S.p.A. ("SIFI"), announced today the development of the Extended Depth-of-Focus (EDOF) intraocular lens, MINI WELL.^®(hereinafter referred to as "MINI WELL^®")" has initiated clinical registration research in China. Professor Lu Yi, Director of the Ophthalmology Institute of the Eye, Ear, Nose and Throat Hospital of Fudan University, and Director of the Cataract Department, along with his team, successfully completed the first patient's artificial lens implantation surgery.

Professor Lu Yi said: "MINI WELL^®Innovative optical design and excellent performance not only extend the depth of field and improve patients' vision at far, intermediate, and near distances but also significantly reduce the occurrence of adverse visual phenomena after cataract surgery. We are very pleased to smoothly advance MINI WELL.^®The first patient enrolled in the registered clinical trial. As the leading unit, the ophthalmology research team of the Eye, Ear, Nose and Throat Hospital affiliated with Fudan University will advance this study with high quality, and we believe that this study will be successfully completed.

Dr. Han Yi, General Manager of AffaMed Technologies, stated: "We will continue to promote the development and use of several innovative intraocular lenses in China, providing more options for cataract and refractive patients, and benefiting Chinese patients."

AffaMed Technologies CEO Dr. Dayao Zhao said: "We are very grateful for the efforts and support of Professor Yi Lu and his team. MINI WELL^®The initiation of the domestic artificial crystalline lens registration clinical trial marks an important milestone in our domestic market development. We look forward to, with MINI WELL^®The clinical development of this product aims to gain regulatory approval, and in the near future, it will bring more benefits in vision correction for patients in China.